Treatment of the syndrome of inappropriate ADH secretion;Traitement du syndrome de sécrétion inappropriée d'ADH

Medecine Therapeutique

Volumn 8, Issue 4, 2002, Pages 204-210

  Decaux, Guy ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMILORIDE; AQUAPORIN; CONIVAPTAN; DEMECLOCYCLINE; DIURETIC AGENT; FUROSEMIDE; KAPPA OPIATE RECEPTOR AGONIST; LITHIUM; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NIRAVOLINE; PHENYTOIN; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TRIAMTERENE; UNCLASSIFIED DRUG; UREA; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

DRUG EFFECT; DRUG INDICATION; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; REVIEW; SYNDROME; WATER DEPRIVATION;

EID: 0036621464     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Bartter F.C., Schwartz W.B. 1967. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42: 790-806.
2. Verbalis J.G. 2001. Escape from antidiuresis: a good story. Kidney Intern 60: 1608-1610.
3. Stormont J.M., Waterhouse C. 1961. The genesis of hyponatremia associated with marked overhydration and water intoxication. Circulation 24: 191-203.
4. Rose B.D. 1986. New approach to disturbances in the plasma sodium concentration. Am J Med 81: 1033-1040.
5. Musch W., Timpont J., Vandervelde D., Verhaeverbeke I., Berghmans T., Decaux G. 1995. Combined fractional excretion of sodium and urea better predicts response to saline in hyponatremia than do usual clinical and biochemical parameters. Am J Med 99: 348-355.
6. Musch W., Decaux G. 2001. Utility and limitations of biochemical parameters in the evaluation of hyponatremia in the elderly. Intern Urol Nephrol 32: 475-493.
7. Musch A., Decaux G. 1998. Treating the syndrome of inappropriate ADH secretion with isotonic saline. Q J Med 91: 749-753.
8. Decaux G., Musch W., Soupart A. 2000. Hyponatremia in the intensive care: from diagnosis to treatment. Acta Clinica Belgica 55: 68-78.
9. Decaux G., Prospert F., Cauchie P., Soupart A. 1990. Dissociation between uric acid and urea clearances in the syndrome of inappropriate secretion of ADH related to salt excretion. Clin Science 78: 451-455.
10. Decaux G., Schesser M., Coffernils M., et al. 1994. Uric acid, anion gap, and urea concentration in the diagnostic approach to hyponatremia. Clin Nephrol 2: 102-108.
11. Decaux G., Musch W., Unger J., Renneboog B., Soupart A. 2001. Low bicarbonate levels in hyponatremia associated with hypopituitarism are due to hypoaldosteronism and help to distinguish these patients from those with non endocrine SIADH. JASN 12: 134A.
12. Decaux G., Przedborski S., Soupart A. 1989. Lack of efficacy of phenytoin in the syndrome of inappropriate secretion of ADH of neurological origin. Postgraduate Medical Journal 65: 456-458.
13. Thibonnier M., Coles P., Thibonnier A., Sholam M. 2001. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonist. Ann Rev Pharmacol Toxicol 41: 175-202.
14. Forrest J.N., Cox M., Hong C., Morrison G., Bia M., Singer I. 1978. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of ADH. N Engl J Med 298: 173-177.
15. Decaux G. 2001. Long-term treatment of patients with inappropriate secretion of ADH by vasopressin receptor antagonist conivaptan, urea or furosemide. Am J Med 110: 582-584.
16. 2-receptor antagonist. Br J Pharmacol 105: 787-792.
17. Saito T., Ishikawa S., Abe K., et al. 1997. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82: 1054-1057.
18. 2 receptor antagonist. Adv Exp Med Biol 449: 439-443.
19. 2 receptor antagonist VPA-985. J Lab Clin Med 138: 8-21.
20. 2 receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-867.
21. 2 receptor antagonist. J Clin Invest 98: 2729-2738.
22. 2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55: 633-637.
23. Decaux G., Brimioulle S., Genette F., Mockel J. 1980. Treatment of the syndrome of inappropriate secretion of ADH by urea. Am J Med 69: 99-106.
24. Decaux G., Genette F. 1981. Urea for long-term treatment of the syndrome of inappropriate secretion of ADH. Br Med J 283: 1081-1083.
25. Decaux G., Unger J., Brimouille S., Mockel J. 1982. Hyponatremia in the syndrome of inappropriate secretion of ADH: rapid correction with urea, sodium chloride, and water restriction therapy. JAMA 247: 471-474.
26. Decaux G., Prospert F., Penninckx R., Namias B., Soupart A. 1993. Five year treatment of the chronic syndrome of inappropriate secretion of ADH with oral urea. Nephron 63: 468-470.
27. Hantman D., Rossier B., Zohlman R., Schrier R. 1973. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of ADH: an alternative treatment to hypertonic saline. Ann Intern Med 78: 870-875.
28. Decaux G., Waterlot Y., Genette F., Mockel J. 1981. Treatment of the syndrome of inappropriate secretion of ADH with furosemide. N Engl J Med 304: 329-330.
29. Decaux G. 1983. Treatment of the syndrome of inappropriate secretion of ADH by long loop diuretics. Nephron 25: 82-88.
30. Ayus J.C., Wheeler J.M., Arieff A.I. 1992. Postoperative hyponatremic encephalopathy in menstruate women. Ann Intern Med 117: 891-897.
31. Arieff A.I. 1986. Hyponatremia, convulsions, respiratory arrest and permanent brain damage after elective surgery in healthy women. N Engl J Med 314: 1529-1535.
32. Soupart A., Decaux G. 1996. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 46: 149-169.
33. Verbalis J.G. 1993. Hyponatremia: epidemiology, pathophysiology and therapy. Curr Opin Nephrol Hypertension 2:636-652.
34. Soupart A., Penninckx R., Stenuit A., Perier O., Decaux G. 1996. Reinduction of hyponatremia improves survival in rats with myelinolysis-related neurologic symptoms. J Neuropath Exp Neurol 55: 594-601.
35. Soupart A., Ngassa M., Decaux G. 1999. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrology 51: 383-386.
36. Oya S., Tsutsumi K., Ueki K., Kirino T. 2001. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology 57: 1931-1932.
37. Soupart A., Penninckx R., Stenuit A., Decaux G. 2000. Uremia decreases the risk of brain damage in rats after correction of chronic hyponatremia. Brain Res 852: 167-172.
38. Soupart A., Silver S., Schroeder B., Sterns R., Decaux G. 2002. Rapid (24 h) re-accumulation of brain organic osmolytes (particularly myo-inositol) in azotemic rats after correction of chronic hyponatremia. J Am Soc Nephrol (sous presse).
39. Soupart A., Penninckx R., Decaux G. 2000. Treatment of severe hyponatremia by urea decreases the mortality rate compared to water diuresis in rats. J Am Soc Nephrol 11: A110 (abstract).